Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsMass General Brigham Lupus Prior Auth | OpenPayer
    Ask Trek AI about this page
    CurrentMass General Brigham Health PlanPolicy N/A

    Lupus Agents: Benlysta (belimumab) and Saphnelo (anifrolumab-fnia) Vials

    Customize your policy alerts

    Sign up for all Mass General Brigham Health Plan policy alerts

    Know when Mass General Brigham Health Plan releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs prior authorization for Benlysta intravenous vial therapy under the MassHealth medical benefit for members with systemic lupus erythematosus or lupus nephritis. It also presents related criteria for Saphnelo vial therapy and applies to providers requesting coverage.

    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyLupus Agents: Benlysta and Saphnelo Vials
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation for Benlysta vial under the MassHealth medical benefit.
    SourceLink
    POLICY UPDATE CHANGES

    The Saphnelo vial criteria were revised to remove the requirement to step through Benlysta or document cutaneous systemic lupus erythematosus.

    Benlysta lupus nephritis criteria added low-dose intravenous cyclophosphamide as an induction-treatment option and added specialist involvement requirements throughout the criteria.

    6 monthsMaximum approval duration

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    5 years
    Minimum Benlysta SLE age
    3Lupus nephritis immunosuppressant options
    90 daysNew-plan treatment lookback
    MedicalVial coverage benefit

    Coverage Criteria

    Benlysta initial therapy for lupus nephritis

    Coverage may be granted when either the new-plan documentation pathway or all initial therapy criteria are met.

    Initial authorization pathway

    • New-plan member documentation

      • The member is new to the plan, as evidenced by a coverage effective date of 90 days or less, and medical records document that the member is currently receiving treatment with Benlysta (belimumab). Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify.Coverage effective date <= 90 days
    • Lupus nephritis criteria

      • Diagnosis of lupus nephritis.
      • Member is at least 5 years of age.>= 5 years
      • The prescriber is a rheumatologist or nephrologist, or consultation notes from a rheumatologist or nephrologist are provided.
      • Required concomitant therapy

        • The requested agent will be used in combination with low-dose glucocorticoids.
        • ONE of the following immunosuppressants

          • Azathioprine.
          • A mycophenolic acid analog.
          • Low-dose intravenous cyclophosphamide as an induction treatment regimen.
      • The requested agent will not be used in combination with other biologics, including rituximab or other B-cell targeted therapies, or with cyclophosphamide as long-term maintenance immunosuppressive therapy.
      • Appropriate dosing is documented.

        Member weight is required for dosing.

    Benlysta initial therapy for systemic lupus erythematosus

    Coverage may be granted when all of the following criteria are met.

    Systemic lupus erythematosus criteria

    • Diagnosis of systemic lupus erythematosus (SLE).
    • Member is at least 5 years of age.>= 5 years
    • The prescriber is a specialist, such as a rheumatologist or dermatologist, or consultation notes from a specialist are provided.
    • Hydroxychloroquine history

      • Inadequate response to hydroxychloroquine.

    For lupus nephritis, Benlysta must be used with low-dose glucocorticoids and one approved immunosuppressant: azathioprine, a mycophenolic acid analog, or low-dose intravenous cyclophosphamide as an induction regimen. Benlysta must not be used with other biologics, including rituximab or other B-cell targeted therapies, or with cyclophosphamide as long-term maintenance immunosuppressive therapy.

    Provider Actions and Authorization Requirements

    Prior Authorization

    Prior Authorization Required

    Prior authorization is required under the MassHealth UPPL for Benlysta (belimumab) vial and Saphnelo (anifrolumab-fnia) vial when billed under the medical benefit. Submit the required clinical documentation with the authorization request.

    • Medical benefit authorization: 833-895-2611; fax 888-656-6671.
    • Auto-injection and prefilled syringe formulations are available only under the pharmacy benefit; consult the MassHealth Drug List for pharmacy-benefit coverage and criteria.
    • Additional agents in this class may be covered under the pharmacy benefit; consult the MassHealth Drug List.
    Prior Authorization

    Six-Month Approval Period

    Approvals may be granted for a maximum of 6 months. Reauthorization by the prescriber will infer a positive response to therapy.

    • Submit a reauthorization request when continued treatment is needed.

    Clinical Background

    Belimumab (Benlysta) is a monoclonal antibody used with standard therapy for active, autoantibody-positive systemic lupus erythematosus in patients 5 years of age and older and for adults with active lupus nephritis. For lupus nephritis, treatment requires concomitant immunosuppressive therapy.

    Covered Indications

    Covered Benlysta indications
    Lupus nephritisActive lupus nephritis in adults receiving standard therapy.
    Systemic lupus erythematosusActive, autoantibody-positive systemic lupus erythematosus in patients five years of age and older receiving standard therapy.
    Saphnelo indication
    IndicationModerate to severe systemic lupus erythematosus in adults receiving standard therapy.

    Initial Therapy

    Benlysta lupus nephritis initial authorization

    Authorization may be granted through the new-plan documentation pathway or when all lupus nephritis criteria are met.

    Initial authorization decision

    • New-plan pathway

      • The member is new to the plan, as evidenced by a coverage effective date of 90 days or less.
      • Medical records document that the member is currently receiving treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify.
    • Lupus nephritis initial criteria

      • Diagnosis of lupus nephritis.

    Reauthorization

    Reauthorization

    Reauthorization by the prescriber will infer a positive response to therapy.

    Continuation therapy

    • The prescriber submits a reauthorization request.
    • Reauthorization by the prescriber indicates a positive response to therapy.Positive response inferred from reauthorization

    Required Prior Therapy

    StepRequired prior therapyQualifying history
    1Hydroxychloroquine before Benlysta for systemic lupus erythematosusInadequate response, adverse reaction, or documented contraindication
    StepRequired prior therapyQualifying history
    2One of the following: azathioprine, methotrexate, mycophenolic acid analog, cyclosporine, cyclophosphamide, or leflunomideInadequate response or adverse reaction to one agent, or contraindication to all listed agents
    Policy Summary
    PayerMass General Brigham Health Plan
    PolicyLupus Agents: Benlysta and Saphnelo Vials
    Policy CodePolicy N/A
    Change TypeRevised
    Effective DateJanuary 4, 2027
    Last ReviewNov 4, 2026
    Next Review DateN/A
    Key ActionSubmit prior authorization documentation for Benlysta vial under the MassHealth medical benefit.
    SourceLink
    On This Page
    Coverage CriteriaProvider Actions and Authorization RequirementsClinical BackgroundCovered IndicationsInitial TherapyReauthorizationRequired Prior Therapy
    Adverse reaction to hydroxychloroquine.
  1. Contraindication to hydroxychloroquine.
  2. Immunosuppressant history

    • Inadequate response or adverse reaction to one of the following: azathioprine, methotrexate, a mycophenolic acid analog, cyclosporine, cyclophosphamide, or leflunomide.
    • Contraindication to all of the following: azathioprine, methotrexate, a mycophenolic acid analog, cyclosporine, cyclophosphamide, and leflunomide.
  3. Appropriate dosing is documented.

    Member weight is required for dosing.

  4. Step Therapy

    Hydroxychloroquine Step

    For systemic lupus erythematosus criteria, document an inadequate response, adverse reaction, or contraindication to hydroxychloroquine before requesting therapy.

    • The requirement applies to the SLE pathway for Benlysta or Saphnelo.

    Unsupported block type: step_therapy

    Unsupported block type: documentation

    Unsupported block type: documentation

    Unsupported block type: denial_risk

    Unsupported block type: denial_risk

    Member is at least 5 years of age.>= 5 years
  5. The prescriber is a rheumatologist or nephrologist, or consultation notes from a rheumatologist or nephrologist are provided.
  6. Required concomitant therapy

    • The requested agent will be used in combination with low-dose glucocorticoids.
    • ONE immunosuppressant

      • Azathioprine.
      • A mycophenolic acid analog.
      • Low-dose intravenous cyclophosphamide as an induction treatment regimen.
  7. The requested agent will not be used in combination with other biologics, including rituximab or other B-cell targeted therapies, or with cyclophosphamide as long-term maintenance immunosuppressive therapy.
  8. Appropriate dosing is documented.

    Member weight is required for dosing.

  9. Benlysta systemic lupus erythematosus initial authorization

    Authorization may be granted when all systemic lupus erythematosus criteria are met. The new-plan documentation pathway may also apply when the member is new to the plan.

    Initial authorization decision

    • New-plan pathway

      • The member is new to the plan, as evidenced by a coverage effective date of 90 days or less.
      • Medical records document that the member is currently receiving treatment with the requested drug. Treatment obtained as samples or through a manufacturer's patient assistance program does not qualify.
    • Systemic lupus erythematosus initial criteria

      • Diagnosis of systemic lupus erythematosus (SLE).
      • Member is at least 5 years of age.>= 5 years
      • The prescriber is a specialist, such as a rheumatologist or dermatologist, or consultation notes from a specialist are provided.
      • Hydroxychloroquine history

        • Inadequate response to hydroxychloroquine.
        • Adverse reaction to hydroxychloroquine.
        • Contraindication to hydroxychloroquine.
      • Immunosuppressant history

        • Inadequate response or adverse reaction to one of the following: azathioprine, methotrexate, a mycophenolic acid analog, cyclosporine, cyclophosphamide, or leflunomide.
        • Contraindication to all of the following: azathioprine, methotrexate, a mycophenolic acid analog, cyclosporine, cyclophosphamide, and leflunomide.
      • Appropriate dosing is documented.

        Member weight is required for dosing.